Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02419495 · ClinicalTrials.gov registry record · Phase 1
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 221
- Enrollment target
NCT02419495: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT02419495 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 221 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02419495, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 221 participants
- Enrollment target
Study Summary
This phase Ib trial studies the side effects and best dose of selinexor when given together with several different standard chemotherapy or immunotherapy regimens in treating patients with malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Selinexor may stop the growth of cancer cells by blocking enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Studying selinexor with different standard chemotherapy or immunotherapy regimens may help doctors learn the side effects and best dose of selinexor that can be given with different types of treatments in one study.
Interventions
- DRUG Cyclophosphamide
- DRUG Carboplatin
- DRUG Capecitabine
- DRUG Doxorubicin
- DRUG Eribulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2015-06-26 |
| Est. Completion | 2024-09-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02419495
The ClinicalTrials.gov registry entry for NCT02419495 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02419495 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02419495 about?
NCT02419495 is a clinical study titled "Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies". This phase Ib trial studies the side effects and best dose of selinexor when given together with several different standard chemotherapy or immunotherapy regimens in treating patients with malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatm...
What is the current status of trial NCT02419495?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 221 participants. The study started on 2015-06-26. Estimated completion is 2024-09-16.
What interventions are being tested in trial NCT02419495?
The interventions under investigation include: Cyclophosphamide (DRUG), Carboplatin (DRUG), Capecitabine (DRUG), Doxorubicin (DRUG), Eribulin (DRUG).
Who is sponsoring clinical trial NCT02419495?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.